Exon skipping induced by CRISPR-directed gene editing regulates the response to chemotherapy in non-small cell lung...

Area of Science:

• Oncology
• Molecular Biology
• Gene Editing

Background:

• Non-small cell lung carcinoma (NSCLC) cells utilize Nuclear Factor Erythroid 2-Related Factor 2 (NRF2) for survival against therapies.
• Disrupting NRF2 is a strategy to enhance anti-cancer drug efficacy.

Purpose of the Study:

• To investigate the consequences of CRISPR-mediated NRF2 disruption in NSCLC.
• To characterize the resulting transcript and protein variations.
• To assess the impact on therapeutic response.

Main Methods:

• CRISPR-directed gene editing targeting NRF2 in NSCLC cells.
• Transcriptome analysis to identify and characterize diverse RNA populations.
• Protein analysis to detect truncated forms.
• Investigation of splicing regulatory elements like Exonic Splicing Enhancers (ESEs).

Main Results:

• NRF2 disruption induced CRISPR-mediated exon skipping, creating heterogeneous transcripts.
• Exon skipping resulted in variable functional domains and truncated proteins.
• A single nucleotide change influenced exon skipping by reorganizing ESEs.
• CRISPR activity generated diverse clones with altered gene expression patterns.

Conclusions:

• CRISPR-mediated NRF2 disruption in NSCLC can cause unintended exon skipping, leading to variable therapeutic responses.
• Careful guide RNA design is crucial to avoid unintended genetic alterations and ensure consistent treatment outcomes.
• Understanding these off-target effects is vital for the clinical application of CRISPR in solid tumor therapy.